Edition:
India

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

12.84USD
11:40pm IST
Change (% chg)

$-0.24 (-1.83%)
Prev Close
$13.08
Open
$13.16
Day's High
$13.16
Day's Low
$12.82
Volume
59,250
Avg. Vol
83,594
52-wk High
$15.08
52-wk Low
$5.45

Latest Key Developments (Source: Significant Developments)

Chemocentryx reports Q3 revenue $9.0 million
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Chemocentryx Inc ::Chemocentryx reports third quarter 2017 financial results and recent highlights.Q3 revenue $9.0 million versus I/B/E/S view $9 million.Chemocentryx Inc - ‍expects to utilize cash and cash equivalents in range of $50 million and $55 million in 2017​.Chemocentryx inc - ‍phase iii advocate trial of avacopan remains on track to complete enrollment in mid-2018​.Chemocentryx Inc - ‍plan to launch registration-supporting trial for CCX140 in treatment of focal segmental glomerulosclerosis (FSGS) in Q4 2017​.Chemocentryx Inc - qtrly loss per share $0.13​.  Full Article

ChemoCentryx qtrly basic and diluted net loss per share $0.19
Wednesday, 9 Aug 2017 

Aug 8 (Reuters) - Chemocentryx Inc :ChemoCentryx reports second quarter 2017 financial results and recent highlights.Q2 revenue $8.9 million versus $2.8 million.Qtrly basic and diluted net loss per share $0.19.  Full Article

Chemocentryx Q1 revenue $8.2 million
Thursday, 11 May 2017 

May 10 (Reuters) - Chemocentryx Inc :Chemocentryx reports first quarter 2017 financial results.Q1 revenue $8.2 million.Chemocentryx Inc- Expects to utilize cash and cash equivalents between $50 million and $55 million in 2017.Chemocentryx Inc - Qtrly basic and diluted net loss per share $ 0.12.  Full Article

Chemocentryx receives FDA orphan drug designation for Avacopan in treatment of debilitating kidney disease
Wednesday, 22 Mar 2017 

Chemocentryx Inc : Chemocentryx receives fda orphan drug designation for avacopan in the treatment of debilitating kidney disease c3 glomerulopathy (c3g) . Chemocentryx inc says plans to initiate a multi-center clinical endpoint study of avacopan for treatment of c3g in first half of 2017 .Chemocentryx inc - u.s. Fda has granted orphan drug designation for avacopan in treatment of patients with c3 glomerulopathy (c3g).  Full Article

Chemocentryx reports Q4 revenue of $4.9 mln
Wednesday, 15 Mar 2017 

Chemocentryx Inc : Chemocentryx Inc - company expects to utilize cash and cash equivalents between $50 million and $55 million in 2017 . Chemocentryx Inc - net losses for Q4 were $7.7 million, compared to $11.6 million for same period in 2015 . Chemocentryx reports fourth quarter and full year 2016 financial results .Q4 revenue $4.9 million.  Full Article

Vifor Pharma, ChemoCentryx announce expansion of Avacopan agreement
Tuesday, 14 Feb 2017 

ChemoCentryx Inc : Vifor Pharma and ChemoCentryx announce expansion of avacopan agreement for rare renal diseases . ChemoCentryx Inc - vifor pharma has gained rights to commercialize avacopan in Asia, including Japan and Middle-East . ChemoCentryx Inc - ChemoCentryx retains all rights in united states and china . ChemoCentryx Inc - agreement gives Vifor Pharma rights to commercialize Avacopan for orphan, rare renal diseases in all markets outside U.S. , China . ChemoCentryx Inc - will receive an upfront cash commitment of usd 20 million in return for new rights, plus tiered double-digit royalties on potential net sales .ChemoCentryx Inc - upfront cash commitment is in addition to usd 85 million upfront paid under original May 2016 licensing agreement.  Full Article

ChemoCentryx says its drug CCX872 well tolerated in clinical trial
Saturday, 21 Jan 2017 

ChemoCentryx Inc : Chemocentryx announces presentation of data from ongoing phase Ib clinical trial of CCR2 inhibitor CCX872 in patients with advanced non-resectable pancreatic cancer .CCX872 has been well tolerated in clinical trial.  Full Article

Vifor Pharma & Chemocentryx expands alliance to include CCX140 to treat renal diseases
Thursday, 22 Dec 2016 

Chemocentryx Inc: Vifor Pharma and Chemocentryx announce expansion of kidney health alliance to include CCX140 to treat renal diseases . Chemocentryx to receive upfront cash commitment of USD 50 million plus potential milestones and royalties . Will be responsible for clinical development of CCX140 in rare renal diseases, while sharing cost of such development with Vifor Pharma . Vifor pharma receives option to develop, commercialize ccx140 in chronic kidney disease with U.S. Co-Promotion rights retained by Co . Co will be eligible to receive tiered double-digit royalties on net sales of CCX140 in licensed territories . Co will be eligible to receive additional payments upon achievement of certain development, regulatory and sales-based milestones .Co Retains marketing rights for rare renal disease in U.S. and China, while Vifor Pharma has commercialization rights in rest of world.  Full Article

ChemoCentryx reports initial results from ongoing phase IB clinical trial of CCX872
Friday, 2 Sep 2016 

ChemoCentryx Inc : Reports initial results from ongoing phase IB clinical trial of CCX872 in patients with advanced pancreatic cancer . Expects to report progression-free survival (PFS) by end of 2016 . CCX872 was well tolerated by advanced pancreatic cancer patients. .Incidence and rate of adverse events were consistent with data reported historically for Folfirinox alone.  Full Article

Chemocentryx reports Q2 revenue of $2.8 million
Tuesday, 9 Aug 2016 

Chemocentryx Inc :Chemocentryx Inc says revenue was $2.8 million for three months ended june 30, 2016 compared to zero in same period in 2015.  Full Article

BRIEF-Chemocentryx Q1 Revenue $9.5 Million Versus $8.2 Million

* CHEMOCENTRYX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS